Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding
Sign Up to like & getrecommendations! Published in 2018 at "Mayo Clinic Proceedings"
DOI: 10.1016/j.mayocp.2017.11.013
Abstract: Objective: To present a multiyear clinical experience with intravenous bevacizumab for the management of severe gastrointestinal bleeding and/or epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). Patients and Methods: All patients treated with intravenous bevacizumab… read more here.
Keywords: hereditary hemorrhagic; gastrointestinal bleeding; hemorrhagic telangiectasia; intravenous bevacizumab ... See more keywords